Wednesday, July 8, 2026

Drug profile · INN

fitusiran sodium

fitusiran sodium (QFITLIA) is an FDA-listed pharmaceutical active ingredient. Route of administration: subcutaneous. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 2
Pipeline programs 3
News articles 0
Drug details — fitusiran sodium
US status
approved
Class
Route
SUBCUTANEOUS
Patents
2
Programs
3
Data quality
0.84

Quick answer

fitusiran sodium (QFITLIA) is an FDA-listed pharmaceutical active ingredient. Route of administration: subcutaneous. Current US regulatory status: approved.

Key facts

INN fitusiran sodium
Brand QFITLIA
Route SUBCUTANEOUS
Formulation SOLUTION

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. fitusiran Phase 3 · Sanofi Pasteur MSD · Hemophilia A
  2. Group A (FIT): Avapritinib + IA regimen Phase 2 · First People's Hospital · Acute Myeloid Leukemia With T(8;21)(Q22;Q22)
  3. SFY17741 Phase 1 · Sanofi-Aventis U.S · Hemophilia A

Related patents

  1. US 9376680

    Serpinc1 iRNA compositions and methods of use thereof

    Expires Mon Jun 23 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 9127274

    Serpinc1 iRNA compositions and methods of use thereof

    Expires Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is fitusiran sodium?

fitusiran sodium (QFITLIA) is an FDA-listed pharmaceutical active ingredient. Route of administration: subcutaneous. Current US regulatory status: approved.

What is the brand name for fitusiran sodium?

QFITLIA is a marketed brand name for fitusiran sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of fitusiran sodium?

fitusiran sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.